CD36 and hyperlipidemia: This is the first study to offer clinical and laboratory evidence of the participation of CD36 in lipotoxicity-induced podocyte FP effacement, suggesting that CD36 could be a therapeutic target for kidney damage accompanied by hyperlipidemia.